Novartis ESMO Event Presentation

Overall survival data interpretation confounded by crossover Crossover: 123/146 (84%) patients who discontinued with radiographic progression 45% information fraction at time of 2nd interim OS analysis Randomized to ARPI N=234 Treatment discontinued N=193 Discontinued due to radiographic progression N=146 Treated with ARPI N=232 Treatment ongoing N=39 OS HR 95% CI Pre-specified primary crossover-adjusted 0.80 (0.48, 1.33) analysis Unadjusted ITT 1.16 (0.83, 1.64) analysis Crossover to Pluvicto N=123 21 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation